This agreement allows a seamless transition of current projects, together with the capabilities, resources and expertise from the TDL to Abzena.
Cambridge, UK, 5 January 2018 – Abzena (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into an agreement with Babraham Bioscience Technologies Limited, (BBT) the company that manages and develops the Babraham Research Campus, to run and develop the services formerly provided by BBT’s Technology Development Laboratory (TDL). This agreement allows a seamless transition of current projects, together with the capabilities, resources and expertise from the TDL to Abzena. These capabilities include enzymatic assay development, small molecule inhibitor screening, molecular biology, cell culture and protein purification. These capabilities will complement and integrate into Abzena’s existing broad range of solutions, including antibody engineering, bioassay and bioanalytical services and cell line development to enable the progress of biopharmaceutical research from discovery through to manufacturing for clinical trials. Abzena will also expand on TDL’s current antibody discovery capabilities to offers its clients a platform for the rapid generation of hybridoma cell lines expressing high affinity antibodies to their chosen target. Campbell Bunce, SVP Scientific Operations, Abzena said: Derek Jones, CEO, Babraham Bioscience Technologies said: |